First, a major business highlight for the quarter was the strategic alliance Regulus entered into last month with GlaxoSmithKline to discover, develop and commercialize novel micro RNA therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.